Cleveland Clinic - Taussig Cancer Center

Taussig Cancer Institute

Cleveland, OH

Sorting 3 by

Accepting patients

SUCCESSOR-1

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)
Learn more
  • CELMoD
  • Randomization
  • Phase 3

Accepting patients

EXCALIBER RRMM

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Learn more
  • CELMoD
  • Randomization
  • Phase 3

Accepting patients

EXCALIBER-Maintenance

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
Learn more
  • CELMoD
  • Post-Autologous Stem Cell Transplant
  • Randomization
  • Phase 3